NVO
Novo Nordisk A/S
- Healthcare
- USD
$39.05
as of 23 Oct 2026, 39% below its 52-week high
Screens as reasonably placed to keep growing its dividend, with low cut-risk signals.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 4.60%Last 12 months of regular payments at today's price
- Forward yield
- 4.60%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- 2.2×Pays 45% of earnings
- Cash cover
- 0.9×Free cash flow over dividends paid
- 5y dividend growth
- +20.1% a yearLast cut in FY2014
- Next ex-dividend date
- Estimated30 Mar 2027Final dividend of about $1.22
Quality
68
ModerateCapacity to keep growing the dividend
Risk
25
LowSignals of dividend-cut pressure
Trim
23
LowHow extended the valuation looks
Why Quality is 68
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of NVO’s past readings.
- P/E16.5×P8, good for this measure
- Yield3.76%P93, good for this measure
- FCF payout106.3%P94, poor for this measure
- Net debt / EBITDA2.47P98, poor for this measure
- DGR 5y+20.1%P79, good for this measure
- ROIC5.6%P0, poor for this measure
Forecast your income with the NVO dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.